Neutralizing antibodies NAb (RBD) to SARS-CoV-2, quantitative — vaccination and immune protection monitoring
Determines neutralizing antibody level to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. Used for vaccination efficacy assessment and immune protection after infection.
Deviation mechanism: Neutralizing antibodies block viral RBD interaction with ACE2 receptor → prevent virus cell entry → form protective immunity. High level indicates reliable protection; low level indicates weak immunity.
Recommended for: patients after COVID-19 vaccination; patients after SARS-CoV-2 infection; risk groups for immune protection monitoring; revaccination planning.
Biomaterial: Venous blood
Fasting is preferred but not required
Exclude alcohol 24 hours before
Avoid physical activity and stress before collection
Immune response monitoring after vaccination; COVID-19 reinfection risk assessment; immune protection monitoring in medical workers and risk groups; revaccination planning.
High titer — reliable immune protection.
Low titer — weak immune response; revaccination may be needed.
Negative — neutralizing antibodies absent.
Results evaluated together with vaccination history and clinical data.
Recommended physicians: Infectious disease specialist or General Practitioner.
